News & Updates
Filter by Specialty:
Topical diclofenac prevents HFS in capecitabine-treated cancer patients
Patients with breast or gastrointestinal (GI) cancer who are being treated with capecitabine monotherapy may benefit from using topical diclofenac gel to prevent or reduce the incidence of hand-foot syndrome (HFS), a common side effect of some chemotherapy drugs, reports a recent study presented at ESMO 2023.
Topical diclofenac prevents HFS in capecitabine-treated cancer patients
15 Nov 2023
Ivarmacitinib efficacious, well tolerated in moderate-to-severe alopecia areata
Use of ivarmacitinib 4- and 8-mg doses for 24 weeks eases hair loss and is generally tolerated in patients with moderate or severe alopecia areata (AA), a phase II study has shown.
Ivarmacitinib efficacious, well tolerated in moderate-to-severe alopecia areata
27 Oct 2023
Histologic margin status predicts relapse in lentigo maligna melanoma
Histologic margin status shows a robust association with progression for lentigo maligna melanoma, suggest the results of a recent study.
Histologic margin status predicts relapse in lentigo maligna melanoma
26 Oct 2023
How safe is long-term bimekizumab in plaque psoriasis patients?
Treatment with bimekizumab (BKZ) for over 3 years does not result in the occurrence of new adverse events (AEs), demonstrating its positive safety profile in patients with moderate-to-severe plaque psoriasis, as shown by a pooled analysis of five phase III/IIIb trials presented at EADV 2023.
How safe is long-term bimekizumab in plaque psoriasis patients?
24 Oct 2023
Risankizumab proven safe, effective in bio-naïve psoriasis patients
Treatment with risankizumab (RZB) results in significantly lower absolute Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI) scores at week 52 in bio-naïve psoriasis patients compared with other biologic therapies, according to the results of a 2-year interim analysis from the German cohort of the VALUE study, presented at EADV 2023.